DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Ovarian Small Cell Carcinoma — screening already-approved drugs against its 14-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOvarian Small Cell Carcinoma maps to a 14-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ovarian small cell carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
Janus kinase 3 (JAK3) — JAK3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet izadrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3LXL · 1.74 Å · ligand 2-TERT-BUTYL-9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLINE-7-ONE (IZA). Experimental structure, not a prediction.
What the evidence adds up to
Ovarian small cell carcinoma is a rare, highly aggressive tumour with two recognised types: the hypercalcaemic type (SCCOHT) and the pulmonary type (SCCOPT). A 2022 case report describes a 23-year-old woman who presented with acute abdomen due to adnexal torsion. After unilateral salpingo-oophorectomy, histopathological evaluation by a team of pathologists confirmed hypercalcaemic small cell carcinoma. The patient refused reoperation, relapsed during chemotherapy, and died six months after initial diagnosis. The authors state that comprehensive information on this cancer is lacking, cytopathological diagnosis remains challenging, and treatments are not usually effective.
A 2013 case series of three patients with small cell carcinoma of the ovary reports rapid progression and spread of disease despite multifactorial therapies. The authors note that no standard treatment has been established for either treatment modalities or outcomes, and that different treatment options administered to these patients were unsuccessful in achieving satisfactory outcomes or disease control. The prognosis is described as very poor with an extremely high mortality rate, except for very rare cases reported in the literature.
A 2015 review of ovarian carcinomas in general describes the heterogeneity of epithelial ovarian cancers and states that immunohistochemistry and molecular testing help pathologists decipher this heterogeneity. It presents improved molecular understanding as a first step toward developing targeted therapies, but does not report any specific treatment results for small cell carcinoma of the ovary.
What is still missing are effective treatments validated in clinical trials, reliable diagnostic criteria that can be applied consistently by pathologists, and any understanding of which patient subgroups might respond to existing therapies. No drug has been shown to improve outcomes in this disease in any of the reported cases.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
癌症：英文版 · 2015 · 75 citations · open access
Pathobiology of ovarian carcinomas
AbstractOvarian tumors comprise a heterogeneous group of lesions, displaying distinct tumor pathology and oncogenic potentiel. These tumors are subdivided into three main categories: epithelial, germ cell, and sex-cord stromal tumors. We report herein the newly described molecular abnormalities in epithelial ovarian cancers (carcinomas). Immunohistochemistry and molecular testing help pathologists to decipher the significant heterogeneity of this disease. Our better understanding of the molecular basis of ovarian carcinomas represents the first step in the development of targeted therapies in the near future.
International Journal of Surgery Case Reports · 2022 · 5 citations · open access
Ovarian small cell carcinoma by ovarian torsion feature
AbstractINTRODUCTION AND IMPORTANCE: Ovarian small cell carcinomas are a rare type of ovarian cancer that is highly aggressive and consists of two distinct types the hypercalcemic type (SCCOHT) and pulmonary type (SCCOPT). CASE PRESENTATION: A 23 years old girl was admitted to the emergency room with the presentation of acute abdomen. The ultrasound and Magnetic resonance imaging revealed a right adnexal huge mass with adnexal torsion. In laparotomy, she underwent unilateral salpingo-oophorectomy due to ovarian torsion and possible malignancy. The histopathological evaluation was challenging and was finalized by a team of pathologists as hypercalcemic small cell carcinoma. She refused reoperation and unfortunately relapsed during chemotherapy and died 6 months after the initial diagnosis. CLINICAL DISCUSSION: Conclusion: We do not yet have comprehensive information on small cell ovarian cancer. Cytopathology diagnosis is still challenging and the treatments are not usually effective. Further clinical trials and studies are recommended to find appropriate treatments for these patients.
Small Cell Carcinoma of the Ovary: Report of Three Cases of a Poor Prognosis Disease
AbstractSmall cell carcinoma of the ovary (SCCO) is a rare, malignant and very aggressive tumor. According to the current state of the art, no standard treatment has been established, both in terms of treatment modalities and outcomes. With the exception of some very rare cases reported in literature, the prognosis remains very poor and mortality rate extremely high. We report of three cases of SCCO with rapid progression and spreading of the disease despite multifactorial therapies. Different treatment options have been administered to our patients, but none of them was successful in achieving satisfactory outcomes and / or disease control. doi: http://dx.doi.org/10.4021/jmc1043e
Journal of Medical Cases · 2013 · 3 citations · open access
Small Cell Carcinoma of the Ovary: Report of Three Cases of a Poor Prognosis Disease
AbstractSmall cell carcinoma of the ovary (SCCO) is a rare, malignant and very aggressive tumor. According to the current state of the art, no standard treatment has been established, both in terms of treatment modalities and outcomes. With the exception of some very rare cases reported in literature, the prognosis remains very poor and mortality rate extremely high. We report of three cases of SCCO with rapid progression and spreading of the disease despite multifactorial therapies. Different treatment options have been administered to our patients, but none of them was successful in achieving satisfactory outcomes and/or disease control. J Med Cases. 2013;4(3):189-192 doi: https://doi.org/10.4021/jmc1043e
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
